258 related articles for article (PubMed ID: 10583021)
1. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase.
Jorga K; Fotteler B; Heizmann P; Gasser R
Br J Clin Pharmacol; 1999 Oct; 48(4):513-20. PubMed ID: 10583021
[TBL] [Abstract][Full Text] [Related]
2. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity.
Smith KS; Smith PL; Heady TN; Trugman JM; Harman WD; Macdonald TL
Chem Res Toxicol; 2003 Feb; 16(2):123-8. PubMed ID: 12588182
[TBL] [Abstract][Full Text] [Related]
3. Determination of the catechol-O-methyltransferase inhibitor tolcapone and three of its metabolites in animal and human plasma and urine by reversed-phase high-performance liquid chromatography with ultraviolet detection.
Heizmann P; Schmitt M; Leube J; Martin H; Saner A
J Chromatogr B Biomed Sci Appl; 1999 Jul; 730(2):153-60. PubMed ID: 10448949
[TBL] [Abstract][Full Text] [Related]
4. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects.
Dingemanse J; Jorga K; Zürcher G; Fotteler B; Sedek G; Nielsen T; van Brummelen P
Eur J Clin Pharmacol; 1996; 50(1-2):47-55. PubMed ID: 8739811
[TBL] [Abstract][Full Text] [Related]
5. The disposition of the tolcapone 3-O-methylated metabolite is affected by the route of administration in rats.
Funaki T; Onodera H; Ushiyama N; Tsukamoto Y; Tagami C; Fukazawa H; Kuruma I
J Pharm Pharmacol; 1994 Jul; 46(7):571-4. PubMed ID: 7996385
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.
Dingemanse J; Jorga K; Zürcher G; Schmitt M; Sedek G; Da Prada M; Van Brummelen P
Br J Clin Pharmacol; 1995 Sep; 40(3):253-62. PubMed ID: 8527287
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics, disposition, and metabolism of [14C]-nebicapone in humans.
Wright LC; Maia J; Loureiro AI; Almeida L; Soares-Da-Silva P
Drug Metab Lett; 2010 Aug; 4(3):149-62. PubMed ID: 20642448
[TBL] [Abstract][Full Text] [Related]
8. Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes.
Lautala P; Kivimaa M; Salomies H; Elovaara E; Taskinen J
Pharm Res; 1997 Oct; 14(10):1444-8. PubMed ID: 9358559
[TBL] [Abstract][Full Text] [Related]
9. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy.
Jorga KM; Fotteler B; Heizmann P; Zürcher G
Eur J Clin Pharmacol; 1998 Jul; 54(5):443-7. PubMed ID: 9754991
[TBL] [Abstract][Full Text] [Related]
11. Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans.
Lave T; Dupin S; Schmitt M; Kapps M; Meyer J; Morgenroth B; Chou RC; Jaeck D; Coassolo P
Xenobiotica; 1996 Aug; 26(8):839-51. PubMed ID: 8879148
[TBL] [Abstract][Full Text] [Related]
12. Identification of metabolite profiles of the catechol-O-methyl transferase inhibitor tolcapone in rat urine using LC/MS-based metabonomics analysis.
Sun J; Von Tungeln LS; Hines W; Beger RD
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Aug; 877(24):2557-65. PubMed ID: 19615953
[TBL] [Abstract][Full Text] [Related]
13. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans.
Dingemanse J; Jorga KM; Schmitt M; Gieschke R; Fotteler B; Zürcher G; Da Prada M; van Brummelen P
Clin Pharmacol Ther; 1995 May; 57(5):508-17. PubMed ID: 7768073
[TBL] [Abstract][Full Text] [Related]
14. Lack of an effect of Madopar on the disposition of tolcapone and its 3-O-methylated metabolite in rats.
Funaki T; Onodera H; Ushiyama N; Tsukamoto Y; Tagami C; Fukazawa H; Kuruma I
J Pharm Pharmacol; 1995 Jun; 47(6):539-42. PubMed ID: 7674141
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.
Jorga K; Fotteler B; Banken L; Snell P; Steimer JL
Br J Clin Pharmacol; 2000 Jan; 49(1):39-48. PubMed ID: 10606836
[TBL] [Abstract][Full Text] [Related]
16. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly.
Jorga KM; Sedek G; Fotteler B; Zürcher G; Nielsen T; Aitken JW
Clin Pharmacol Ther; 1997 Sep; 62(3):300-10. PubMed ID: 9333106
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and elimination of the catechol-o-methyltransferase inhibitor tolcapone in the horse.
Stanley S; Van den Berg K; Foo HC; Deng D
Drug Test Anal; 2019 Apr; 11(4):578-585. PubMed ID: 30367738
[TBL] [Abstract][Full Text] [Related]
18. Absorption, metabolism and excretion of opicapone in human healthy volunteers.
Loureiro AI; Rocha F; Santos AT; Singh N; Bonifácio MJ; Pinto R; Kiss LE; Soares-da-Silva P
Br J Clin Pharmacol; 2022 Oct; 88(10):4540-4551. PubMed ID: 35508762
[TBL] [Abstract][Full Text] [Related]
19. Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites.
Jorga KM; Kroodsma JM; Fotteler B; Heizmann P; Meyer J; Rasch MC; van Hattum J
Clin Pharmacol Ther; 1998 Jun; 63(6):646-54. PubMed ID: 9663179
[TBL] [Abstract][Full Text] [Related]
20. Metabolism, distribution and excretion of a selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in rats and dogs.
Prakash C; Cui D; Potchoiba MJ; Butler T
Drug Metab Dispos; 2007 Aug; 35(8):1350-64. PubMed ID: 17496205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
